Hemolysis-Associated Endothelial Dysfunction and Pulmonary Hypertension: An Emerging Cause of Death in Hemolytic Anemias
Einstein-Montefiore Department of Medicine Grand Rounds
Thursday, January 14, 2010
First Floor Lecture Hall, Forchheimer/Einstein
Cherkasky Auditorium, Moses/Montefiore
Mark T. Gladwin, MD
Professor of Medicine
Division Chief, Pulmonary, Allergy and Critical Care Medicine
Director, Hemostasis and Vascular Biology Research Institute (HVBRI)
University of Pittsburgh, PA
Dr. Mark Gladwin received his M.D. from the University of Miami Honors Program in Medical Education in 1991. After completing his internship and chief residency at the Oregon Health Sciences University in Portland, Ore., he joined the NIH in 1995 as a critical care fellow in the Clinical Center. After completion of a clinical fellowship in pulmonary medicine at the University of Washington in Seattle, he returned for a research fellowship at the NIH Critical Care Medicine Department, Clinical Center, under the mentorship of James Shelhamer, Frederick Ognibene, Alan Schechter, and Richard Cannon. He later served as the Chief of the Pulmonary and Vascular Medicine Branch within the NHLBI, NIH.
In August of 2008, Dr. Gladwin became Chief of the Pulmonary, Allergy and Critical Care Medicine Division at the University of Pittsburgh School of Medicine and the Director of the newly formed Hemostasis and Vascular Biology Research Institute.
He is the author or co-author of 117 original research publications. In recognition of his research, Dr. Gladwin has been elected to membership in the American Society for Clinical Investigations (ASCI, 2006) and the Association of American Physicians (AAP, 2009); he received the NIH Merit Award (2006) in recognition for accomplishments in both basic and clinical sciences in the use of nitrite and NO in clinical applications.
This week's Medical Grand Rounds is entitled the Ron Nagel Red Cell Lecture in recognition of the immediate past chief of the Division of Hematology.
This grand rounds is hosted by the Division of Hematology.
After attending this activity, participants will be able to:
- Describe the epidemiology and clinical presentation of pulmonary hypertension (PH) in sickle cell disease (SCD)
- Apply diagnostic and treatment options for patients with PH of SCD
- Recognize the interplay of genetics, hemolysis and decreased nitric oxide bioavailability in PH of SCD
Albert Einstein College of Medicine designates this educational activity for a maximum of 1 credit towards the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.